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Studies on the occurrence of pharmaceuticals show that the widely used pharmaceuticals ibuprofen and diclofenac are present
in relevant concentrations in the environment. A pilot plant treating hospital wastewater with relevant concentrations of these
pharmaceuticals was evaluated for its performance to reduce the concentration of the pharmaceuticals. Ibuprofen was completely
removed, whereas diclofenac yielded a residual concentration, showing the necessity of posttreatment to remove diclofenac, for
example, activated carbon. Successively, detailed laboratory experiments with activated sludge from the same wastewater treatment
plant showed bioremediation potential in the treatment plant. The biological degradation pathway was studied and showed a
mineralisation of ibuprofen and degradation of diclofenac. The present microbes were further studied in laboratory experiments,
and DGGE analyses showed the enrichment and isolation of highly purified cultures that degraded either ibuprofen or diclofenac.
This research illuminates the importance of the involved bacteria for the effectiveness of the removal of pharmaceuticals in a
wastewater treatment plant. A complete removal of pharmaceuticals from wastewater will stimulate water reuse, addressing the
worldwide increasing demand for clean and safe fresh water.
1. Introduction
Since the last 10–20 years the quality of surface water systems
and their interacting groundwater systems is increasingly
under pressure as a result of new groups of chemicals
entering these natural water systems. The occurrence of
organic micropollutants such as pharmaceuticals, synthetic
hormones, and personal care products has the increasing
attention of drinking water companies and water resource
institutions. Furthermore, the development of analytical
techniques to measure these compounds at low concentra-
tions has accelerated this awareness. In the last 40 years,
technologies for the removal and recovery of bulk substances
from wastewater effluents, such as organics and nutrients
like phosphorus and nitrogen, have been developed and
implemented into the water cycle infrastructure. As these
technologies are designed to deal with bulk load emissions,
many organic micropollutants are not removed during the
passage through these systems [1].
Organic micropollutants such as pharmaceuticals enter
thewater cycle either as the original compound or in ametab-
olized form at low loads [2], resulting in relatively low con-
centrations, that is, in the ng/L–𝜇g/L range [3, 4]. The upper
range of these concentrations is found in wastewater that
originates from the so-called hot-spots such as hospitals or
elderly houses. These concentrations have most likely been
present in the water since many years, and their levels have
only recently been quantified and acknowledged as a poten-
tial ecological risk. The recent development of new analytical
techniques has allowed us to detect such low concentrations
in the environment. Although they are often present in
low concentration, various studies into effects on quality
and ecological functioning of water systems show that these
chemicals form a potential new problem. Their estrogenic
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and carcinogenic toxicity will impact the quality of ecological
life and possibly also of human life [5]. There are currently
no legally regulated maximum permitted concentrations of
pharmaceuticals in the environment. If we are able to remove
these organicmicropollutants in a cost effectivemanner from
wastewater, This will reduce their environmental impact on
natural water sources and soil. In addition, an optimised
water reuse helps to limit the use of fresh water, which is a
growing concern in rivers worldwide.
Studies on the occurrence of pharmaceuticals show that
the widely used pharmaceuticals ibuprofen and diclofenac
(Figures 1(a) and 1(b)) are present in relevant concentrations
in the environment [4]. Both ibuprofen and diclofenac are
non-steroidal drugs, used against pain, fever and inflamma-
tion and can be used without prescription. The yearly use of
ibuprofen and diclofenac in the Netherlands in 2009 has been
estimated at 22.600 kg and 5.200 kg, respectively [6].
Efficient removal of low concentrations of ibuprofen and
diclofenac from wastewater has to occur at a time scale of
minutes to days due to the short retention time in a treat-
ment plant. Currently, highly selective and rapid reactions
turned out to be efficient to remove micropollutants, such as
advanced oxidation processes (AOPs) that use combinations
of reactive oxidants including ozonation, photocatalyses, and
ultrasound oxidation [7–10] or adsorbents such as activated
carbon [11]. AOPs are characterized by the production of
extremely reactive and unselective species such as hydroxyl
radicals, which are able to degrade recalcitrantmolecules into
possible biodegradable intermediate compounds or com-
pletely mineralize them into CO
2
, H
2
O, and inorganic ions.
However, this may also lead to the formation of potentially
harmful by-products, and such oxidation technologies are
characterized by a large ecological footprint due to a high
energy use [4]. In addition, many of these systems are under
research and have yet to be applied on a large scale since there
is a lack of good quality data on themechanisms involved, the
influence of operational variables, the reaction kinetics, and
reactor design issues.
In principle, biological techniques can bemore robust and
cost-effective for the removal of micropollutants compared
to oxidation technologies [12], but many micropollutants
are not sufficiently removed in the currently operated high
organic loaded biological water treatment systems that focus
on chemical oxygen demand (COD) and nutrient removal
[13].
In the literature, various removal rates are described for
the biological removal of both ibuprofen and diclofenac; for
example, diclofenac showed low removal rates (21.8± 28.5%)
in a pilot-scale membrane bioreactor, whereas ibuprofen
showed a removal of 99.1 ± 1.8% [14]. In general, ibuprofen
reported removal rates are among the highest ones of all phar-
maceuticals, as ibuprofen is known for its easy biodegrad-
ability, and removal rates of over 95% are often mentioned in
lab-scale and wastewater treatment plants [15]. Interestingly,
in many cases pharmaceutical loads increased during the
wastewater treatment, resulting in a removal efficiency above
100%, due to fluctuating sorption and desorption of the
pharmaceuticals to organicmatter. Recently, also constructed
wetlands were found to effectively remove pharmaceuticals,
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Figure 1: Chemical structure of ibuprofen (a) and diclofenac (b).
with ibuprofen removal following predominantly microbial
aerobic degradation [16].
More detailed biodegradation studies with batch tests
and flow-through soil columns under unsaturated, aero-
bic conditions also demonstrated biodegradation for phar-
maceuticals, such as ibuprofen and diclofenac [17]. Only
one study describes anaerobic lab-scale experiments that
show 30–60% removal of ibuprofen under anoxic conditions
and up to 80% degradation of diclofenac [18]. Recently,
the complete aerobic removal of ibuprofen and diclofenac
was demonstrated with the white rot fungus Phanerochaete
chrysosporium in fed-batch bioreactors [19]. This shows that
there are currently various bioreactors being tested for their
removal capacity which are effective for the treatment of
organic micropollutants.
So far, little is known about bacteria that degrade these
pharmaceuticals and the involved biodegradation pathways,
for example, only one bacterial strain has been described that
degrades ibuprofen and uses ibuprofen as carbon and energy
source [20]. Diclofenac has been shown to be biodegradable,
but the responsible bacteria are unknown. In addition, the
white rot fungus Phanerochaete chrysosporium is able to
completely degrade ibuprofen and diclofenac [19].
The objectives of this study were (1) to determine the
removal of ibuprofen and diclofenac in a pilot membrane
bioreactor (MBR), (2) to investigate the biological transfor-
mation of the pharmaceuticals and the effect of electron
acceptor and the presence of an easily degradable substrate
(acetate or toluene) on the removal of the pharmaceuticals,
and (3) to get more insight in the degradation pathway
and the involved bacteria. This allows us to get insight into
the biodegradation processes, including enrichment of the
responsible bacteria, elucidating the degradation pathways,
and evaluation of the removal of these pharmaceuticals in a
wastewater treatment plant.
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2. Materials and Methods
2.1. Wastewater Treatment System. Wastewater from a hospi-
tal inTheNetherlands was treated in a pilot wastewater treat-
ment system. Pretreatment consisted of screening (6mm)
and sieving (0.5mm wide openings) of the wastewater.
The wastewater treatment plant consisted of a membrane
bioreactor (MBR), with various posttreatment steps. The
bioreactor was aerated with compressed air generated by two
compressors and distributed by fine bubble disc aerators.
The membrane unit was positioned outside the reactor.
The flow of the liquid was outward through the tubular
membranes.NineHyperflux tubularmodules (MO83G I8LE
BA, Berghof) made of fiber reinforced polymer resin with
a membrane area surface of 27.2m2/module were used. The
bioreactor was operated at an average temperature of 17.4∘C,
an organic loading rate of 0.032 kg BOD/kgTS/d, and anHRT
of minimal 28 hrs.
Based on the expected daily amount of wastewater, an
average flow rate of 10m3/h was chosen, with a maximum
flowof 25m3/h.The total volume of theMBRwas 280m3.The
plant was designed to treat chemical oxygen demand concen-
trations of 490–690mg/L COD and an average concentration
of total solids (TS) of 6 g/L, making it an ultra-low loaded
reactor. As a result, sludge was discharged in low quantities,
resulting in a high sludge retention time (SRT).
Various posttreatment lines were installed in parallel:
(i) granular activated carbon, (ii) ozone treatment with
and without H
2
O
2
addition, (iii) ozone treatment with and
without H
2
O
2
addition, followed by GAC, (iv) UV/H
2
O
2
treatment, and (v) reversed osmosis treatment.
2.2. Batch Experiments. Aerobic and anaerobic batch exper-
iments (microcosms) have been performed in duplicate in
120mL bottles with medium and activated sludge from two
conventional municipal treatment plants inTheNetherlands:
(1) adapted sludge from a sewage treatment plant and (2)
unadapted sludge from a recently started membrane biore-
actor.
For the aerobic batch experiments, 120mL bottles were
filledwith 40mL aerobicmedium and 2mL sludge and sealed
with butyl rubber or Viton rubber stoppers (Rubber BV,
Hilversum,TheNetherlands).The aerobic medium consisted
of (per liter of demineralized water) 3.5 g Na
2
HPO
4
⋅2H
2
O, 1 g
KH
2
PO
4
, 0.01 g Fe-ammonium citrate, 1 g (NH
4
)
2
SO
4
⋅7H
2
O,
0.04 g MgSO
4
⋅7H
2
O, and 8mg CaCl
2
⋅2H
2
O. Vitamins and
tracerswere added according to themediumused by de Bruin
et al. [21]. Autoclaved controls were taken along as well.
For the batch experiments under anoxic conditions, the
medium as described for the aerobic batches was prepared
anaerobically while continuously flushing with N
2
gas and
the addition of nitrate (0.85 to 3.4 g/L NaNO
3
). Resazurin,
a colour indicator to control anoxic conditions, was added
at a final concentration of 0.5 𝜇g/L. After closing the bottles,
the gas phase in the bottles was changed to 80%N
2
/20% CO
2
(v/v) and brought to 1.3 bar.
The pharmaceuticals ibuprofen and diclofenac were
added at a concentration of 50mg/L and in further experi-
ments gradually increased to 250 and 300mg/L, respectively.
Initially, pharmaceuticals, dissolved in methanol, were added
to the batches, after which themethanol was evaporated.This
was only done in the first experiments with unadapted sludge.
In later experiments, the pharmaceuticals were dissolved in
small volumes of medium, filter sterilised, and added after
autoclaving.
Stimulated or cometabolic degradation of the pharma-
ceuticals was tested by the addition of acetate (5 to 50mM)
or toluene (12.5 to 250𝜇M). Viton rubber stoppers were
used when toluene was added to the batches. Acetate
or toluene was measured routinely and readded upon
depletion.
The bottles were incubated on a shaker (100 rpm) in the
dark at 30∘C. Autoclaved controls were taken along as well.
The concentrations of ibuprofen or diclofenac weremeasured
routinely. Oxygen or nitrate was measured routinely and
added when depleted.
2.3. Enrichment of Bacteria. Batch cultures were used to
further isolate the pharmaceutical degrading bacteria by
dilution series in either aerobic liquid medium or on agar
plates. Dilution series in medium were made in 115mL
serum bottles with 40mL aerobic medium as described
above, by transferring 4mL from the batch culture to fresh
medium, followed by transferring 4mL of the latter into
40mL fresh medium and repeated several times. The bottles
were incubated on a shaker (100 rpm) in the dark at 30∘C.
The agar plates were made with aerobic medium as de-
scribed above and 15 g/L agar. After cooling of the medium,
0.1mL of the microbial dilution series was spread on the
agar plate with a sterile glass rod. The agar plates were
placed upside down to prevent condensation on the agar and
incubated in the dark at 30∘C.
2.4. Molecular Analyses. The purity of the cultures was tested
by Polymerase Chain Reaction (PCR) andDenaturing Gradi-
ent Gel Electrophoresis (DGGE). DNA was extracted using
a FastDNA SPIN Kit for Soil (MP Biomedicals). Bacterial
primers 968F GC, 1401R [22] and archaeal primers Arc344F
GC [23] and Arc915R [24] were used for the amplification
of the 16S rRNA. The final volume of 50 𝜇L PCR mixture
contains 10 𝜇L 5x green gotaq reaction buffer (Promega), 1𝜇L
of each primer, 1𝜇L deoxynucleoside triphosphate (dNTP),
0.25 𝜇L Taq DNA polymerase (Promega), and 5 𝜇L template
DNA (sample). PCRwas performed under the following con-
ditions: preheating to 94∘C for 2min. or 5min. for bacterial or
archaeal PCR, respectively. For PCR using bacterial primers
35 amplification cycles of denaturation at 94∘C for 30 sec.,
primer annealing for 40 sec. at 56∘C, and extension for 1min.
at 72∘Cwere performed followed by a final extension of 5min.
at 72∘C. PCR using archaeal primers was performed using 35
cycles of denaturation for 10 sec. at 94∘C, primer annealing for
20 sec. at 61∘C, which was decreased every cycle until 56∘C,
and extension for 40 sec. at 72∘C.This was followed by a final
extension at 72∘C for 30min.
DGGE analysis was performed as described before [25],
and gels were stained with AgNO
3
according to Sanguinetti
et al. [26].
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2.5. Analytical Procedures. Toluene was analysed on a Gas
Chromatograph (GC; Shimadzu GC 2010) equipped with
a Sil5 CB column (25m; Chrompack, Middelburg, The
Netherlands). Headspace samples (0.4mL) were taken from
the batch experiments and directly analysed for their toluene
concentration on the GC. The GC was operated in constant
flow mode, and the column temperature was 80∘C. Toluene
was detected with a Flame Ionisation Detector (FID) at
300∘C. External standards of toluene at five different concen-
trations from 0 to 300 𝜇Mwere used for calibration.
The concentration of acetate was measured using High
Performance Liquid Chromatograph (HPLC Varian, Mid-
delburg, The Netherlands). Prior to analyses, liquid samples
from the batch experiments were acidified with 0.04M
H
2
SO
4
to pH 2, and 30 𝜇L sample was injected onto the col-
umn (Metacarb 67H 300mm column; Varian, Middelburg,
The Netherlands). The flow rate was 0.8mL/min with an
isocratic eluent of 0.01N H
2
SO
4
in Milli-Q water. Detection
was performed using a UV detector at a wavelength of
220 nm. Sodium crotonate was used as an internal standard
at a concentration of 6mM, and external standards of sodium
acetate at five different concentrations from 0 to 20mMwere
used for calibration.
Oxygen was analysed by gas chromatography. Headspace
samples of 0.4mL were taken from the batch experiments
and directly injected onto a Shimadzu GC-14B (Shimadzu,
Kyoto, Japan) equipped with a packed column (Molsieve
13X, 60–80mesh, 2m length, 3mm internal diameter; Varian,
Middelburg, The Netherlands) and a thermal conductivity
detector set at 70mA. The GC was operated in constant flow
mode, with an injector temperature of 80∘C. The column
temperature was 100∘C, and the detector temperature was
130∘C. Argon was used as the carrier gas at a flow rate
of 30mL/min. Calibration was done with air samples (21%
oxygen) and 100% nitrogen samples.
Nitrate was analysed by anion exchange chromatography
(Dionex DX-120l; Dionex Breda, The Netherlands). Sam-
ples (20𝜇L) were injected onto an IONPAC AS22 column
(Dionex, Breda, The Netherlands) operated at 35∘C.The flow
rate was set to 1.2mL/min with an eluent of 4.5mM Na
2
CO
3
and 1.4mM Na
2
CO
3
in Milli-Q water. Bromide (1mM) was
added as an internal standard, and external standards of
NaNO
3
at five different concentrations from 0 to 20mMwere
used for calibration.
Ibuprofen and diclofenac were analysed using liquid
chromatography mass spectrometry (UPLC-MS/MS). Sam-
ple clean-up for the samples from the batch experiments
consisted of centrifuging (5min, 13,000 rpm) to remove the
sludge, followed by diluting the supernatantwith acetonitrile-
water (40% : 60%) to obtain a maximum concentration of
5mg/L. The injection volume was 20 𝜇L. Liquid chromatog-
raphy consists of a Waters Chromatography Acquity UPLC
separation module, equipped with an Acquity UPLC HSS T3
column (1.7 𝜇m ∗ 100 ∗ 2.1mm ID) at 65∘C. The LC mobile
phase consisted of amixture of 0.1% acetic acid inwater (solu-
tion A) and 0.1% acetic acid in acetonitrile (solution B). A
linear gradient was used with 60% B for 1min, followed by
an increase to 95% in 0.1min, 3min. at 95%, and finally a
decrease to 60% in 0.1min.
Mass-spectrometer (MS) analysis was carried out with
a Waters-Micromass Ultima Platinum. Depending on com-
pound, the measurement was carried out in positive or
negative electrospray ionisation (ESI) mode. The measure-
ments were performed in negative ionisation mode with the
following settings: a capillary voltage of 1.2 kV, a cone voltage
of 35V, RF lens 1 of: 5, aperture at 0.5, and RF lens 2 at 1.0.The
source temperature was 120∘C, and desolvation temperature
was 325∘C.The cone gas flowwas 116 L/hr, and the desolvation
gas flow was 701 L/hr. LM1/HM1 resolution was 14, with an
ion energy of 0. LM2/HM2 resolution was 14.5, with an ion
energy of 1.0. The collision cell pressure was 3.06e-03, and
the collision cell entrance was 10, with a CE gain of 1 and exit
0. The MRM transitions for ibuprofen and diclofenac were,
respectively, 205.0 > 161.1 and 294.0 > 250.0.
Internal standards of deuterated ibuprofen and diclofenac
were used in concentrations of 1mg/L. External standards
of ibuprofen and diclofenac at five different concentrations
ranging from 0 to 5mg/L were used for calibration.
Intermediates were analysed by liquid chromatography
time of flight mass spectrometry (LC-ToF-MS). Samples
from the incubations were centrifuged (5min, 13,000 rpm)
to remove the sludge before injection onto the LC system,
and 90𝜇L was mixed with 10 𝜇L acetonitrile and acidified
with acetic acid (final concentration 0.01%).The sampleswere
injected at a Bruker microToF-Q coupled via an ESI interface
to a Waters Acquity system with column oven. A Waters
BEH-C18 column (150mm × 2.1mm, 1.7𝜇m; 4.6 × 150mm,
df = 3.5 𝜇m) was used with a mobile phase A (water) and B
(acetonitrile). Initially, 5%Bwas used for 0.3min, followed by
an increase of 80% in 5min, an increase of 95% B in 0.1min.,
maintained at 1min., and finally an increase to its initial
conditions of 5% B. The column oven was set to 60∘C and
the mobile phase flow was set at 0.6mL/min. The injection
volume was 50 𝜇L.
The LC-ToF-MS measurements were performed in nega-
tive ionizationmode. Datawere collected from 50 to 1000m/z
with a scan time of 1 second. The electrospray voltage of
the ion source was set at 2500V. The nebulizer gas flow
was 2.0 bar, and drying gas flow was 5 L/min. The drying
temperature was set at 200∘C. The transfer time of the
source was 100 𝜇s, and the hexapole radiofrequency (RF) was
400Vpp.
The instrument was tuned and calibrated before analysis.
At the beginning, during, and at the end of the analysis, an
internal mass calibration solution was added via an injection
port. This calibration solution contained sodium formate. By
the use of this internal calibration mix the each individual
compound was mass corrected. Instrument resolution (full
width at half maximum) was approximately 20000 for m/z
10000.
3. Results and Discussion
Apilot wastewater treatment plant treating hospital wastewa-
ter with amembrane bioreactor (MBR) and several posttreat-
ment steps was evaluated for its removal of 44 pharmaceuti-
cals, including ibuprofen and diclofenac. The MBR received
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Figure 2: Influent and effluent concentrations of ibuprofen and
diclofenac in a membrane bioreactor, operated with wastewater
from a hospital.
concentrations that varied from 4 to 12 𝜇g/L ibuprofen and
2 to 4 𝜇g/L diclofenac (Figure 2). The concentration profile
in the effluent was measured using UPLC-MS/MS during the
first months after start-up and showed effective removal of
ibuprofen below the detection limit of 0.01 𝜇g/L but not for
diclofenac, yielding a residual diclofenac concentration (Fig-
ures 2 and 3). This poor biological degradation of diclofenac
in the MBR can be due to various factors; for example, the
degrading bacteria are not present, the degradation rate is
too low (e.g., a higher hydraulic retention time is needed),
environmental conditions are not suitable for degradation
(nutrients, pH, temperature), and so forth. A higher retention
time has previously been suggested for other treatment
systems, where the influence of various HRT on the removal
rate of pharmaceuticals was demonstrated [27].
Alternatively, physical-chemical posttreatment stepswere
needed to effectively remove pharmaceuticals from the
wastewater. Various posttreatment steps were tested in this
study for the removal of diclofenac; see Table 1. Ozonation
and reversed osmosis were most effective in the removal of
diclofenac, but also granular activated carbon showed a good
removal of the present diclofenac (95%). Ibuprofen was not
studied in the posttreatment steps, as it was already removed
in our MBR.
To date, information on the treatment of pharmaceuticals
in various treatment systems is scarce. The use of physical-
chemical posttreatment steps has been described in a few
studies and our results are in line with recent studies,
where the use of activated carbon to adsorb pharmaceuticals
has been successfully described [28–31]. The advantage of
activated carbon is that it removes pharmaceuticals without
the generation of toxic active products as by, for exam-
ple, UV/peroxide oxidation or ozone treatment. Like our
posttreatment results showed, these technologies have also
been shown to effectively remove pharmaceuticals [7–10].
However, this may also lead to the formation of potentially
harmful by-products, and such oxidation technologies are
characterized by a large ecological footprint, due to a high
energy use [4], which might make them less attractive for
application.
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Figure 3: Removal percentages of ibuprofen and diclofenac in a
membrane bioreactor, operated with wastewater from a hospital.
Table 1: Removal percentage of diclofenac in various posttreatment
systems of the membrane bioreactor.
Posttreatment Diclofenac removal
Granular activated carbon (GAC) 95.0%
Ozone unit 99.5%
Ozone unit with H2O2 addition 99.5%
Ozone unit and GAC 99.5%
UV/H2O2-system 80.0%
Reversed osmosis 99.5%
To get more insight in the degradation processes in this
MBR, the responsible microbes, and the underlying degra-
dation mechanisms, laboratory experiments were performed
to test the potential for aerobic and anaerobic degradation
of ibuprofen and diclofenac. Microcosms were started with
sludge from two treatment plants as inoculum; (i) a sludge
that was adapted to concentrations of pharmaceuticals and
(ii) unadapted sludge from an MBR reactor sampled shortly
after start-up and only exposed to low concentrations of
pharmaceuticals. Initial experiments were performed with
both sludges, the individual pharmaceuticals in the presence
of oxygen or nitrate, and the presence of an extra carbon
and energy source, respectively, acetate or toluene.Thebottles
were fully closed to prevent any evaporation out of the bottle.
Oxygen was measured routinely and added when depleted.
Both ibuprofen and diclofenac were degraded in the
presence of oxygen within 27 days of incubation (Figure 4).
Controls without sludge or without electron acceptors (oxy-
gen and nitrate) did not show any decrease in the con-
centration of the two pharmaceuticals (results not shown).
The aerobic degradation of both ibuprofen and diclofenac
in the incubations with adapted sludge was two to five
times faster compared to the incubations with the sludge
from the MBR (Figure 4). This indicates that the microbial
populations in the two inocula show a different affinity
towards the degradation of the selected pharmaceuticals. For
diclofenac, this effect was more pronounced in the MBR,
with no diclofenac removal (Figure 3), compared to the initial
6 BioMed Research International
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Figure 4: Degradation of 50mg/L ibuprofen and diclofenac in
batches with activated sludge from a municipal wastewater treat-
ment plant andunadapted sludgewith oxygen or nitrate after 27 days
of incubation. Standard deviations in data shown were 10%.
microcosms that showed a slow degradation. Theoretically,
the reduced degradation in the batches with MBR inoculum
may also be affected by the presence of methanol in the
initial batches, that was used to dissolve the pharmaceuticals
to the batches. However, the lower removal rate in the
MBR itself is related to the microbial population present.
Other studies describe diverse effects of the presence of
biodegradation activity prior to elevated exposure. After
providing higher concentrations, either comparable or higher
biological degradation rates were found [32].
Acetate or toluene was added to the batches to pro-
mote biomass growth, suggesting that they could serve as
a primary substrate in a cometabolic transformation of
the pharmaceuticals. In our experiments, the addition of
acetate or toluene in the initial incubations resulted in a
slower degradation of ibuprofen and diclofenac, most likely
due to competition for the different substrates and electron
acceptors, similar to competing substrate consumption in raw
or treated wastewater [17]. Other studies that tested the effect
of acetate dependent behaviour of ibuprofen and diclofenac
degradation showed varying results ranging from no effect of
acetate, to acetate concentration controlled degradation [33,
34]. This shows that the concentration and character of other
organic carbon present in wastewater effluents can affect the
degradation efficiency of pharmaceuticals. The differences in
the trends of these literature data and our studies are likely
due to different experimental designs (microcosms, column
studies). These studies vary in retention times, temperature,
the presence of nutrients, and so forth, and highlight the
need for further research to study parameters that affect the
transformation of pharmaceuticals.
After the degradation of the initial concentration of
50mg/L in the incubations with ibuprofen as carbon and
energy source, the concentration ibuprofen was gradually
increased to 75mg/L, 100mg/L, and a final concentra-
tion of 250mg/L. This highest concentration of ibuprofen
(250mg/L) was degraded within 4 days (Figure 5). The
diclofenac concentration was not increased but kept at
50mg/L since the degradation rate was much lower.
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Figure 5: Degradation of ibuprofen and diclofenac in microcosms,
after 2 subsequent transfers, resulting in 2nd generation cultures.
Standard deviations in data shown were 4%.
All microcosms under anoxic conditions with nitrate
as electron acceptor showed no significant degradation of
the pharmaceuticals (Figure 4), and these conditions were
not further studied in this research. Our experiments were
performed with aerobic sludge as inoculum, providing pre-
dominantly a pool of aerobic bacteria that were not adapted
to anoxic conditions. As many nitrate reducing bacteria are
also able to reduce nitrate, our inoculum should be suitable to
enrich bacteria that could degrade diclofenac with nitrate as
electron acceptor. Nevertheless, we were not able to establish
degradation with nitrate as electron acceptor. Other research
has reported an initial decrease in diclofenac concentration
in batch experiments with nitrate as electron acceptor, but
considering the concentration established towards the end
of the experiments, they concluded that no overall removal
of diclofenac occurred [35]. Whether sorption or desorption
played a role in the rebounding of the concentration was not
elucidated by the authors.
The degradation of ibuprofen was fast (50mg/L within 27
days) in the aerobic microcosms, and no intermediates could
be detected by LC-ToF-MS analyses during the degradation.
Known intermediates that have been detected in incubations
with activated sludge are hydroxyibuprofen, carboxyibupro-
fen, and carboxy hydratropic acid [36]. Isobutylcatechol,
5-formyl-2-hydroxy-7-methylocta-2,4-dienoic acid and 2-
hydroxy-5-isobutylhexa-2,4-dienedioic acid were detected
during the degradation of ibuprofen with Sphingomonas sp.
strain Ibu-2 [20]. Recently, also 1,2-dihydroxy ibuprofen was
identified as an intermediate [37]. None of those could be
detected in our degradation studies, indicating either a dif-
ferent degradation pathway, or more likely, a mineralization
to CO
2
and H
2
O without the accumulation of intermediates.
When diclofenac was degraded, eight different metabo-
lites were observed in our enrichments, of which only three
have been found in other studies: 2-((2,6-dichloro-phenyl)
amino)benzyl alcohol methyl ether [38], and the undefined
compounds M190 and M340 with a mono-isotopic mass of
322.99673 and 338.9953, respectively, as described by Pe´rez
and Barcelo´ [39]. LC-ToF-MS analyses showed five further
intermediates with a mono-isotopic mass of, respectively,
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Figure 6: DGGE gel loaded with PCR products from enrichment
cultures and purification experiments. The sample ID is given on
top of the gel, and is from left to right: marker, blank, i1a, i1b, i2a,
i2b, i3, i4, i5, marker, i6, i8, d3, d4, d5, d6, i7, marker.
305.9835, 310.9984, 315.9923, 325.9869, and 383.9797. Iden-
tification of these metabolites was not achieved, making it
impossible to further identify the degradationmechanisms of
ibuprofen or diclofenac in our study. In general, hydroxylated
metabolites are most likely to be formed during the aerobic
degradation of diclofenac although we did not find such
compounds in our batch experiments.
After several transfers into fresh media, aerobic enrich-
ment cultures with ibuprofen or diclofenac as carbon and
energy source degraded the pharmaceuticals up to concentra-
tions of 250mg/L ibuprofen or 300mg/L diclofenac. Higher
concentrations were not tested. These concentrations (mg/L)
are significantly higher than those found in wastewater
treatment plants (𝜇g/L instead of ng/L) but were needed
for our experimental set-up to transfer, enrich, and obtain
purified bacterial cultures.
These batches were used to further isolate the pharma-
ceutical degrading bacteria by dilution series in either liquid
medium or on agar plates and were used to obtain bacterial
cultures on ibuprofen and diclofenac. Single colonies on agar
plates were inoculated in fresh liquid media and showed
prolonged degradation of the pharmaceuticals. In order to
link observed degradation with the purity of the microbial
community during the degradation, an assessment of the
microbial population was made through DGGE profiling.
Molecular analyses of ibuprofen and diclofenac degrading
cultures showed further enrichment along the dilution series
when looking at the DGGE profile of the various samples
(Figure 6). The highly enriched cultures on ibuprofen (i7) or
diclofenac (d6) both originate from an isolated culture on an
agar plate, and show a DGGE profile with only 2 bands. This
indicates the presence of a highly enriched bacterial culture
with only one species with two copies of the 16s DNA or
two different bacterial species.This demonstrates that specific
ibuprofen or diclofenac degrading bacteria were present in
the original used inoculum from the wastewater treatment
plants, and that they can be used to enhance the treatment
of the pharmaceuticals in the wastewater. The necessity of a
complete removal of pharmaceuticals from wastewater will
stimulate water reuse technologies, addressing the worldwide
increasing demand for clean fresh water resources. For this,
the development of innovative, effective, and sustainable
microbiological removal technologies for organic micropol-
lutants in waste water is needed.
4. Conclusions
Our study shows that the pilot MBR treating hospital waste
removed ibuprofen below the detection limit of 0.01 𝜇g/L
whereas diclofenac was not removed in the MBR. Posttreat-
ment was needed for an efficient removal of all pharmaceuti-
cals in the wastewater.
The pharmaceuticals were aerobically degraded inmicro-
cosms, with ibuprofen being faster degraded than diclofenac.
The degradation was not enhanced by the presence of acetate
or toluene as primary substrates, and the degradation of
the pharmaceuticals in the presence of nitrate as electron
acceptor was not observed. 250mg/L ibuprofenwas degraded
within 4 days to undetectable concentrations, and 75% of
the added 300mg/L diclofenac was degraded within 3 weeks.
Higher concentrations were not tested.
Our experiments showed the degradation of both ibupro-
fen and diclofenac, with no intermediates detection for the
degradation of ibuprofen, whereas several intermediates of
the degradation pathway of diclofenacwere identified.DGGE
analyses of the enrichment culture on ibuprofen or diclofenac
showed that highly purified cultures were obtained, with only
two bands on the DGGE gel, indicating either one or two
bacterial species.
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